Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Separation Science



View Channel

Microscopy | Image Analysis



View Channel

IT Solutions and Laboratory Automation



View Channel


Conferences | Events

Agilent Announces Unique Portfolio to Advance Immunotherapy

publication date: May 28, 2019
author/source: Agilent Technologies


Innovative solution provides cell-based tools for translational research and development

20190515_2Agilent Technologies Inc. announces a unified portfolio of products for immunotherapy researchers. The innovative solution was on display at Immunology 2019, the 103rd Annual Meeting of the American Association of Immunologists (AAI), which took place in San Diego, CA on May 9-13, 2019.

“Immunotherapy is changing the landscape of cancer treatment, but most of the available tools are adapted and not purpose-built for this cell-centric workflow,” said David Ferrick, Ph.D., senior director of the Cell Analysis Division at Agilent Technologies. “This is why we have placed so much emphasis on assembling and harmonizing innovative cell-based solutions. We want to enable researchers and developers to overcome the challenges and capture the opportunities of this rapidly growing field.”

“To find the answers, flow cytometry approaches, kinetic measures of live-cell metabolism, and quantifying the ability of T cells to kill targets over time, are all aspects that can be investigated now with the tools that Agilent provides,’ said Carl June, MD, professor in immunotherapy at the Perelman School of Medicine at the University of Pennsylvania and Abramson Cancer Center. “Any cell-based assay that improves the probability that you’re going to have an effective cell product will be something that everyone wants.”


Agilent’s new offering includes four purpose-built components that naturally complement:


  • Agilent SureGuide Chemically Synthesized sgRNAs: Deliver the best guides to enable the full potential of CRISPR for cellular engineering and immunotherapy.
  • NovoCyte Quanteon Flow Cytometer: Quickly and accurately immunophenotype with up to 25 channels of fluorescence using the most sensitive silicon photomultiplier detector technology on the market. Experience the new standard in flow cytometry.
  • xCELLigence RTCA eSight: Capture dynamic cell behavior and follow the biology that can be missed by labor-intensive endpoint assays to quantify, in real-time critical events like cancer cell killing.
  • Agilent Seahorse XF Analyzers: Discover and tune immune cell metabolism to mount a sustained and robust anti-tumor response. XF analyzers are the market leading choice for this type of work.

An Agilent workshop titled Breakthroughs in immunotherapy: Tune the drivers of immune cell potency, fate and persistence, was presented by David Ferrick.


About Agilent Technologies Inc.

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.91 billion in fiscal 2018 and employs 15,300 people worldwide.


more news from Agilent


If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners